Contents
Highlights………………………………………………………………………3
RPC1603 RADIANCE trial……………………………………………………4
Daclizumab DECIDE trial…………………………………………………….5
Tecfidera DEFINE, CONFIRM, and ENDORSE long-term follow-up……6
Treatment practices in first and second-line patients……………………..7
Tysabri usage and JCV testing………………………………………………7
anti-CD20 therapies……………………………………………………………8
Myelin desensitization therapies……………………………………………..9
Anti-LINGO and myelin regeneration therapies……………………………10
Tysabri ASCEND trial upcoming data……………………………………….11